We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Medical Device Maker Stryker Sets Eye on China

By HospiMedica International staff writers
Posted on 29 Jan 2013
Stryker Corporation (Stryker, Kalamazoo, MI, USA) has agreed to buy Trauson Holdings (Hong Kong) for USD 764 million in cash to expand in China, one of the fastest-growing markets for medical products.

With the acquisition, Stryker will expand its presence with a product portfolio and pipeline that is targeted at a large and fast growing segment of the Chinese orthopedic market. More...
Under the terms of the agreement, Stryker will make a voluntary general offer to acquire all the shares of Trauson in an all cash transaction, representing an enterprise value of approximately USD 685 million. Trauson's controlling shareholder, Luna Group, has undertaken to accept the offer from Stryker by tendering 61.7% of the Trauson shares toward the offer.

Founded in China in 1986, Trauson had sales in 2011 approximating USD 60 million, and it is the leading trauma manufacturer in China and a major competitor in the spine segment. Stryker and Trauson have maintained a relationship under an original equipment manufacturer (OEM) agreement for instrumentation sets since 2007. Trauson’s research and development expertise, manufacturing capabilities, and strength of its distribution network could provide Stryker with a vehicle to drive growth in China and other emerging markets.

“The acquisition of Trauson is a critical step toward broadening our presence in China and developing a value segment platform for the emerging markets through a well-established brand,” said Kevin Lobo, president and CEO of Stryker. “The acquisition of a leading player in the Chinese trauma and spine market underscores our commitment to strengthening our presence globally.”

“I am very proud to have worked with everyone associated with Trauson to build the company from its beginning 27 years ago into the largest orthopedic products producer in China,” said Trauson Chairman Fuqing Qian. “The orthopedics market in China has great growth potential. The combined scale, local and global expertise, complementary product offerings, and market breadth of Trauson and Stryker will create significant competitive advantages in the increasingly dynamic orthopedic, industry and provide a platform to fully realize the future growth opportunities in China and globally.”

Stryker, which has a market capitalization of nearly USD 23 billion, makes surgical implants, spine devices, and other medical equipment.

Related Links:
Stryker Corporation
Trauson Holdings




Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
12-Channel ECG
CM1200B
New
Complete Hip System
Taperloc Complete Hip System
New
Mobile X-Ray Machine
MARS 15 / 30
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: A mechanosensing-based approach offers a potential path to the treatment for cardiac fibrosis (Photo courtesy of Adobe Stock)

Mechanosensing-Based Approach Offers Promising Strategy to Treat Cardiovascular Fibrosis

Cardiac fibrosis, which involves the stiffening and scarring of heart tissue, is a fundamental feature of nearly every type of heart disease, from acute ischemic injuries to genetic cardiomyopathies.... Read more

Surgical Techniques

view channel
Image: Bioprinting synthetic vasculature could dramatically change how cardiovascular diseases are treated (Dell, A.C., Maresca, J., Davis, B.A. et al.; doi.org/10.1038/s41598-025-93276-y)

Bioprinted Aortas Offer New Hope for Vascular Repair

Current treatment options for severe cardiovascular diseases include using grafts made from a patient's own tissue (autologous) or synthetic materials. However, autologous grafts require invasive surgery... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.